Clinical trial

Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer

NCT01942837

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-09-13

PhasePHASE2

Study timeline

Study start (actual)2013-09-13Date precision: day

Registry last updated2022-10-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Castration-resistant Prostate Cancerunresolved

Interventions

EnzalutamideDRUG · verified · RxNorm: enzalutamide

Sponsors & collaborators

Dana-Farber Cancer Institutelead sponsor

Medivation, Inc.collaborator

Mapped research locations

BostonMassachusetts, United States3 SeattleWashington, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01942837 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.